Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine in Borderline Personality Disorder
NCT00091650Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in borderline personality disorder (BPD) comparing Olanzapine with Placebo (2 arms). Primary endpoint: Zanarini Rating Scale for Borderline Personality Disorder Total Score at 12 weeks. Started Mar 2004; status: completed.
02
Drugs
olanzapine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT00091650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091650.